An observational study in Erosive Gastroesophageal Reflux Disease, sponsored by Jeil Pharmaceutical Co., Ltd.. Recruiting at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by Jeil Pharmaceutical Co., Ltd. · Observational
This post-marketing surveillance aims to evaluate the safety and effectiveness of zastaprazan citrate administered in Korean patients receiving the drug in accordance with the approved prescribing information.
Jeil Pharmaceutical Co., Ltd. is the lead sponsor of 37 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study population will include patients aged 19 years or older who receive their first prescription for zastaprazan citrate in accordance with the approved prescribing information at participating study sites in South Korea. The first prescription must be issued after execution of the study agreement with the respective site. Eligible patients who provide written informed consent will be enrolled consecutively.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients administrated zastaprazan citrate
Drug: zastaprazan citrate
There is no treatment allocation in this study. Patients who are prescribed zastaprazan citrate at the discretion of their treating physicians will be enrolled consecutively. Zastaprazan citrate will be administered in accordance with the approved prescribing information.
Percentage of Participants With Adverse Events
The percentage of participants who experience at least one adverse event during the observation period will be calculated. Adverse events will be assessed for seriousness, expectedness based on the approved prescribing information, and causal relationship to zastaprazan citrate. This assessment will identify serious and non-serious adverse drug reactions, including known and unexpected reactions. Events relevant to the safety concerns specified in the risk management plan will also be reviewed.
Time frame: From enrollment to the end of treatment at 8 weeks
Plan to share: No
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Jeil Pharmaceutical Co., Ltd. →